Semaglutide

I Kekemapa 2017, ua ʻae ka US Food and Drug Administration (FDA) i ka papa inoa o Smeglugan peptide injection i ka hoʻokele meaʻai kōkua a me ka hoʻomaʻamaʻa e hoʻomaikaʻi i ka hoʻokele glucose koko o nā maʻi me ka maʻi diabetes type 2.Eia kekahi, ua hoʻomohala ʻo Novo a me Nord i ke ʻano o ka waha waha Rybelsus o Smeglugin, a ua ʻae mua ʻia e FDA i Kepakemapa 2019. ʻO kēia hoʻi ka lāʻau GLP-1 waha mua i ʻae ʻia ma ka honua.diabetes.ʻO ka mea nui, ʻo Smeglugin kahi lāʻau hypoglycemic, akā no ka mea hiki i nā lāʻau lapaʻau e like me Smeglugin peptide ke hoʻolōʻihi i ka ʻōpū a hoʻopau i ka makemake, e hoʻemi ia i ke kaumaha.

I ka ʻike ʻana i kēia, i Iune 2021, ua ʻae ʻo FDA i ka hoʻokele paona lōʻihi o ka momona a i ʻole nā ​​​​mākua.ʻO nā kānaka kūpono: nā maʻi maʻalahi me BMI ≥30 kg / m2;a me BMI> 27 kg/m2 a hoʻohui i hoʻokahi pilikia o ka momona, e like me ke kiʻekiʻe kiʻekiʻe, ka maʻi maʻi type 2, a i ʻole nā ​​lipid koko ʻino.ʻO ia hoʻi ka ʻae ʻana i kanu ʻia ka ʻike no Smeglugin ma ke ala o "ka lāʻau kilokilo hoʻēmi kaumaha".

I ʻApelila 2021, ua ʻae ʻia ʻo Smegugan ma Kina no ka mālama ʻana i ke kō koko no nā poʻe maʻi me ka maʻi diabetes type 2 (T2DM).ʻOiai ʻaʻole ʻae ʻia ka hōʻailona o ke kaumaha ma Kina, ʻaʻole hiki ke mālama ʻia ke koi no ka pohō kaumaha o ka home ma Kina.Eia kekahi, ʻo ke kumumanaʻo nui o ka "thinness with thinness", i ka lua o ka hapa o 2022, ʻo Smeglugin peptide "ʻaʻole i ʻae" i ke kahua o ka pohō kaumaha., I kekahi manawa ma nā papahana e-commerce he nui, ua hoʻomaka ʻo ia i ka boom i ke kūʻai ʻana, a ua lilo ia i kumu kūʻai kiʻekiʻe "ma waho o ke kumukūʻai aliʻi", i alakaʻi pololei i nā pilikia o ka hana a me ka lako o nā mea hana.Ua ʻōlelo ʻo Nuo a me Nord i Iulai i ka makahiki i hala ʻO ka hoʻomau ʻana o ka hoʻolako ʻana i ka lāʻau lapaʻau e hoʻopau i ka hoʻolako ʻana i nā mākeke ma waho o ka haukapila.

Ua hōʻoia ʻia ka kaulana o Smegugu peptide mai ka ʻikepili kālā o Nuo a me Nord.Wahi a nā hopena 2022 i hoʻolaha ʻia e Nuo a me Nord, ʻo ka loaʻa kālā makahiki o ka ʻoihana ʻo Nuo a me Nord's GLP-1 ʻo 83.371 biliona ʻo Dan Ying Crown (e like me 81.6 biliona yuan), kahi piʻi o 56% makahiki ma ka makahiki.Ma waena o lākou, ʻo ke kūʻai aku ʻana o Smeglugin he 59.75 biliona Dan Ying Crown (e like me 58.5 biliona yuan), kahi hoʻonui o 77% makahiki-ma-makahiki.Ua hoʻonui ʻia ka hana kūʻai aku o nā huahana GLP-1 ma ke kahua o ka maʻi diabetes type 2 ma Kina e 102% ma Dan Ying Krone.

ʻOiaʻiʻo, ʻo ka pahū ʻana o Smeglugin i ke kahua o ka pohō kaumaha e pili kokoke ana i kona hopena koʻikoʻi."ʻO ka manawa kēia e ʻai ai, inu a inu, lawe i 5 paona paona, lilo i 30 paona i Ianuali" a pēlā aku.Eia kekahi, hiki ke ʻoi aku ka lahilahi o ka "moe palahalaha", ka mea i huki i nā maka he nui i nā peptides Smegtu, i ʻike mua ʻia ʻo "lāʻau kilokilo kilokilo".Eia naʻe, ua ʻōlelo kekahi mau kauka lapaʻau ʻo Simei Gulu peptide i ʻoi aku ma mua o 2/3 o nā kūʻai kūloko ma Kina e lilo i ke kaumaha, ʻaʻole i ka maʻi diabetes.Ma ka ʻaoʻao hoʻokahi I ka ʻōlelo o Smeglugan peptide ma ke ʻano he lāʻau lapaʻau, aia nā pōʻino huna i ka palekana o nā lāʻau lapaʻau superpatient.

He mea pono e hoʻomaopopo i ka hopena o ka noiʻi kūloko o ia mau lāʻau lapaʻau mai nā poʻe maʻi obesity nui.No ka poʻe me ka momona iki a i ʻole ke kaumaha maʻamau (BM <27kg/m2), ʻaʻole ʻike ʻia nā pōmaikaʻi a me nā pilikia.Eia kekahi, ma ka hoʻohui ʻana i nā hopena o ka hypoglycemia he mau lāʻau hypogenal i loaʻa i nā lāʻau hypoglycemic, ʻoi aku ka nui o nā hopena o ka ʻōpū, a ʻo ka nui o ka nausea, constipation, luaʻi a me ka maʻi maʻi e like me 82.8%.7%.ʻO ka mea nui loa ʻaʻole i ʻae ʻia ʻo Smeglugin no nā hōʻailona pohō kaumaha ma Kina.ʻO ka pilikia o nā ala lāʻau lapaʻau a me ka hoʻohana ʻana i ka lāʻau lapaʻau o ia poʻe pono e nānā.